| Company |
Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen,
Germany,
Tel.: +49 (0)214 87632-0, www.biofrontera.com |
| Strategy
| Biofrontera develops a product portfolio for dermocosmetical products and drugs for dermatological
and inflammatory diseases. The company's goal is to establish its own dermatology
marketing and sales force in selected European countries, out-licensing
the distribution of products in other countries and in indications outside
dermatology. |
| Business
| Biofrontera positioned itself as an integrated specialty-pharma
company. The focus on dermatology and composition of a broad clinical pipeline
illustrate the market potential of the Company. First market introduction
is expected for projects with moderate risks of failure, such as reformulations
or applications for approved drugs in new indications. Establishing own
marketing and sales will maximize the added value of the Company. The long-term
pipeline management is based on a combination of product acquisition, in-licensing
and in-house research. |
| Company structure
| Biofrontera AG is a holding with two wholly-owned subsidiaries,
Biofrontera Bioscience GmbH and Biofrontera Pharma GmbH.
|
| Drug Pipeline
|
| Compound |
Status |
| Belixos |
Market launch Oct 2009 |
| BF-200 ALA |
Clinical development completed for actinic keratosis |
| BF-derm1 |
Completed clinical Phase II for antihistamine-refractory urticaria |
| BF-1 |
In clinical development for migraine prophylaxis
|
|
| Technologies
| Biofrontera's specific expertise resides in the characterization
of the pharmacological properties of drug candidates in vitro and in vivo.
|
| Patents
| Biofrontera's product portolio is protected by a series of patent families. |
| Management
| Prof. Hermann Lübbert, PhD, CEO
Werner Pehlemann, CFO
Fabian Esser, PhD, Head of Marketing & Sales
|
| Team
| With just 24 highly skilled and trained employees, Biofrontera
functions as a lean and efficient organization. |
| Supervisory Board
| Jürgen Baumann (Chairman), Andreas Kretschmer,
LLD (Vice Chairman), Richard Gabriel, BS, MBA, Ulrich Granzer, PhD, Heinrich Hornef, PhD, Prof. Bernd Wetzel, PhD
|
| Finance
| Since 1997 Biofrontera has raised EUR 27.4 mln from investors
and EUR 8 mln in grants from federal and state governments and the European
Union.
In August 2005 Biofrontera listed a EUR 20 mln convertible bond at the Frankfurt
stock exchange.
In October 2006 Biofrontera successfully closed a private placement of 443,514
new shares at a price of EUR 15 per share, generating additional cash of
EUR 6.65 mln. All new investors were granted the option to sign up for additional
shares at a fixed price of EUR 15. Through the placement of the option shares in 2007 Biofrontera has obtained
additional funding of EUR 3.33 mln..
On October 30th 2006 Biofrontera listed its shares in the regulated market
(geregelter Markt) of the Düsseldorf stock exchange. The shares are
registered under the symbol B8F and the ISIN number DE0006046113.
In August 2008, January 2009, May 2009 und December 2009 Biofrontera had small capital increases, providing the company with a total of 6.5 mln Euro.
|
| Goals
| European approval of BF-200 ALA expected for 2011
|
